Novo Nordisk narrows guidance slightly in Q3 report

Sales development is currently anticipated to be 23-27% at CER in 2024 contrasted to a previous 22-28%, while running earnings development is currently anticipated to be 21-27% at CER as opposed to 20-28%.

发布者:BY CATHERINE BRETT,转转请注明出处:https://robotalks.cn/novo-nordisk-narrows-guidance-slightly-in-q3-report/

(0)
上一篇 11 11 月, 2024
下一篇 11 11 月, 2024

相关推荐

发表回复

您的电子邮箱地址不会被公开。 必填项已用 * 标注

联系我们

400-800-8888

在线咨询: QQ交谈

邮件:admin@example.com

工作时间:周一至周五,9:30-18:30,节假日休息

关注微信
社群的价值在于通过分享与互动,让想法产生更多想法,创新激发更多创新。